Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

6.92
Delayed Data
As of May 24
 +0.25 / +3.75%
Today’s Change
5.02
Today|||52-Week Range
13.00
-12.41%
Year-to-Date
Merrimack/Baxalta Start Study on Colorectal Cancer Drug
May 20 / Zacks.com - Paid Partner Content
More Picks for a Rough Market
May 19 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close6.67
Today’s open6.70
Day’s range6.68 - 7.03
Volume1,856,927
Average volume (3 months)1,904,822
Market cap$883.9M
Dividend yield--
Data as of 05/24/2016

Growth & Valuation

Earnings growth (last year)-66.25%
Earnings growth (this year)--
Earnings growth (next 5 years)+5.61%
Revenue growth (last year)-13.14%
P/E ratioNM
Price/Sales9.86
Price/Book--

Competitors

 Today’s
change
Today’s
% change
FOLDAmicus Therapeutics ...+0.22+3.18%
LCILannett Company Inc+0.78+3.49%
SRPTSarepta Therapeutics...+0.96+5.49%
SUPNSupernus Pharmaceuti...+0.44+2.39%
Data as of 05/24/2016

Financials

Next reporting dateAugust 8, 2016
EPS forecast (this quarter)-$0.25
Annual revenue (last year)$89.3M
Annual profit (last year)-$148.0M
Net profit margin-165.76%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Robert J. Mulroy
Head-
Corporate Operations
William M. McClements
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs